Venstra Medical

About Venstra Medical

Venstra Medical develops a percutaneous ventricular assist device pVAD that delivers 7 liters per minute at 60 mmHg through a 9F delivery system, providing temporary cardiac support during critical procedures. This technology addresses the high mortality risk associated with cardiogenic shock and supports patients undergoing percutaneous coronary interventions.

```xml <problem> Cardiogenic shock and high-risk percutaneous coronary interventions (PCI) present significant mortality risks for cardiac patients due to dangerously low cardiac output or the need for circulatory support during procedures. Existing solutions may be too invasive or lack sufficient pumping capacity. </problem> <solution> Venstra Medical is developing a next-generation percutaneous ventricular assist device (pVAD) designed to provide temporary cardiac support. The device is delivered through a 9F delivery system and is capable of pumping 7 liters per minute at 60 mmHg. This pVAD aims to improve outcomes for patients experiencing cardiogenic shock or undergoing high-risk PCI by providing effective circulatory assistance with a less invasive approach. </solution> <features> - Percutaneous ventricular assist device (pVAD) for temporary cardiac support - 7 liters per minute pumping capacity at 60 mmHg pressure - 9F delivery system for less invasive implantation - Designed for use in cardiogenic shock and high-risk PCI procedures </features> <target_audience> The primary target audience includes cardiologists and hospitals treating patients experiencing cardiogenic shock or undergoing high-risk percutaneous coronary interventions (PCI). </target_audience> ```

What does Venstra Medical do?

Venstra Medical develops a percutaneous ventricular assist device pVAD that delivers 7 liters per minute at 60 mmHg through a 9F delivery system, providing temporary cardiac support during critical procedures. This technology addresses the high mortality risk associated with cardiogenic shock and supports patients undergoing percutaneous coronary interventions.

Employees
3 employees

Venstra Medical

4
Relative Traction Score based on online presence metrics compared to companies in the same age group.

Executive Summary

Venstra Medical develops a percutaneous ventricular assist device pVAD that delivers 7 liters per minute at 60 mmHg through a 9F delivery system, providing temporary cardiac support during critical procedures. This technology addresses the high mortality risk associated with cardiogenic shock and supports patients undergoing percutaneous coronary interventions.

venstramedical.com50+

Funding

No funding information available.

Team (<5)

No team information available.

Company Description

Problem

Cardiogenic shock and high-risk percutaneous coronary interventions (PCI) present significant mortality risks for cardiac patients due to dangerously low cardiac output or the need for circulatory support during procedures. Existing solutions may be too invasive or lack sufficient pumping capacity.

Solution

Venstra Medical is developing a next-generation percutaneous ventricular assist device (pVAD) designed to provide temporary cardiac support. The device is delivered through a 9F delivery system and is capable of pumping 7 liters per minute at 60 mmHg. This pVAD aims to improve outcomes for patients experiencing cardiogenic shock or undergoing high-risk PCI by providing effective circulatory assistance with a less invasive approach.

Features

Percutaneous ventricular assist device (pVAD) for temporary cardiac support

7 liters per minute pumping capacity at 60 mmHg pressure

9F delivery system for less invasive implantation

Designed for use in cardiogenic shock and high-risk PCI procedures

Target Audience

The primary target audience includes cardiologists and hospitals treating patients experiencing cardiogenic shock or undergoing high-risk percutaneous coronary interventions (PCI).

Sources:

1
This profile is AI-generated from web data and may contain inaccuracies. Want to correct or remove an entry? Owners can claim edits via their company email domain, and signed-in users can submit sourced suggestions.